Scilex Holding Company (SCLX) — Titan Protect Analysis

SCLX

Scilex Holding Company

Healthcare · ·

$7.00

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$50M

Total market value of the company

Trailing P/E

N/A

Forward P/E

9.81

Based on estimated future earnings — lower means cheaper

Rev Growth

+72.1%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura

https://www.scilexholding.com

Country: United States Employees: 34 Industry: Drug Manufacturers - General

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.112

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0260

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.585

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-55.4%

Historical annualised return based on price data

Max Drawdown

-94.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.79

Significantly more volatile than the market

52W High

$34.27

80% below the year high

52W Low

$4.20

67% above the year low

Avg Volume

72,682

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-40.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

59.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-373.5%

Profit from core operations before interest and tax

Free Cash Flow

$6M

Positive — the business generates more cash than it spends

Revenue (TTM)

$34M

Total revenue over the last 12 months

Net Income

$-419,676,992

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go